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Background: Many studies have suggested that hepatitis B virus (HBV) genotypes show not only geographical
distribution and race specificity, but also are associated with disease progression and response to interferon
treatment. The objective of this study was to develop a nested polymerase chain reaction (nPCR) assay for
genotypes A-D and subgenotypes B1, B2, C1 and C2 of hepatitis B virus (HBV) and to investigate the distribution
characteristics of HBV genotypes/subgenotype in China.
Methods: After redesigning the primers and optimizing the reaction conditions using common Taq polymerase,
the sensitivity, specificity and reproducibility of the method were evaluated using plasmids and serum samples. In
total, 642 serum samples from patients with chronic HBV infection were applied to investigate the distribution of
HBV genotype and subgenotype in China.
Results: The genotype and subgenotype could be identified when the HBV DNA load of a sample was
≥102.3 IU/mL. For the 639 successfully genotyped samples, the sequencing results of 130 randomly selected
samples (20.3%, 130/639) were consistent with those of the nPCR method. The present study showed that HBV
genotype B (11.2%, 72/642), C (68.2%, 438/642) and D (7.2%, 46/642) were circulating in China, while genotype C
was the dominant strain except for western region where genotype D was the prevalent strain. The main
subgenotypes of genotypes B and C were B2 (87.5%, 63/72) and C2 (92.9%, 407/438), respectively.
Conclusions: The low-cost nPCR method would be a useful tool for clinical and epidemiological investigation in
the regions where genotypes A-D are predominant.
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An increasing number of studies have suggested that
hepatitis B virus (HBV) genotypes show not only geo-
graphical distribution and race specificity, but also are
associated with disease progression and response to
interferon treatment [1,2].
According to sequence divergence of greater than 8%
over the entire genome, or greater than 4% for the S gene,
HBV has been classified into eight different genotypes A-H* Correspondence: Jielipku@gmail.com; zhuangbmu@126.com
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reproduction in any medium, provided the or[3-6]. Different subgenotypes for each genotype have also
been identified and defined by sequence divergence of
between 4% and 8% of the full genome [7].
Hepatitis B is endemic in China, with a hepatitis B sur-
face antigen (HBsAg) carrier rate of 7.18% [8]. HBV mo-
lecular epidemiological studies showed that genotypes B
and C were predominant in China. Genotype A (few and
scattered), D (predominant in Uyghur patients of
Xinjiang) and C/D recombinant (mainly found in Tibet)
were also detected in China [9,10]. The predominant
subgenotype of B was B2, and that of C was C2, while
B1 and C1 were also present in China [11].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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quence analysis of the entire genome [3] or of the S gene
[4] is considered as the gold standard for genotyping.
Other methods include type-specific PCR [12-15], re-
striction fragment length polymorphism assay (RFLP)
[16-18], line probe assay [19], and specific monoclonal
antibody assay [20,21], etc. Among these methods, the
type-specific PCR method has been used widely for clin-
ical and epidemiological surveys due to its rapid detec-
tion, low cost, high specificity and sensitivity, and
superior results for the diagnosis of mixed infections
[22].
Dr. Naito and his colleagues developed a type-specific
nPCR method for genotyping of HBV in 2001 [15], and
it was considered as a classical method. Following Nai-
to’s method, one round type-specific PCR (multiplex
PCR) methods was developed by some scholars [12-14].
Our lab adopted Naito's method for genotyping since
2002. However, in long-term use of the method in our
lab, it was found that the specificity of the method was
reduced when common Taq polymerase was employed
instead of AmpliTaqGold DNA polymerase (unpublished
data). Moreover, Naito's method could not identify sub-
genotypes directly. Among one round type-specific PCR,
Chen's method [12] was reported to be superior in spe-
cificity and sensitivity, and could distinguish subgeno-
types in another reaction. However, our study showed
that the sensitivity of the method for genotypes B and C
was >104 IU/mL (the procedures exactly followed those
as reported). Other studies also showed similar results
about the sensitivity of Chen’s method [23,24].
Considering the importance of genotyping and subge-
notyping of HBV in clinical and epidemiology surveys, a
more specific, sensitive and low-cost method is required.
This study established a type-specific nPCR assay for
genotypes A-D and main subgenotypes of HBV B and C,
based on modification of the PCR method developed by
Naito et al., (2001) [15], and it was applied to investigate
the distribution of HBV genotypes and subgenotypes in
China. Using this method, 642 samples from patients




Plasmids containing genomic DNA of HBV genotype A
[25], genotype D [26], subgenotype B1 [27] and subgeno-
type C2 [25] were employed in this study. Serum sam-
ples of HBV subgenotype B2 and C1, which were
confirmed by sequencing, were employed as standard
sera [GenBank: JQ416307, JQ416308]. All of the samples
were stored at −80 °C before testing.
One hundred and twenty seven serum samples were
selected randomly from the serum bank and were usedfor evaluating the sensitivity of the nPCR method. All of
the samples with an HBV DNA load of ≥102.3 IU/mL
could be genotyped. A further 543 samples with an HBV
DNA load of ≥102.3 IU/mL were then selected from the
serum bank. Therefore, a total of 642 clinical serum
samples from patients with chronic HBV infection were
enrolled in this study.
These serum samples enrolled in this study were col-
lected from the east (Shandong and Jiangsu), the west
(Xinjiang), the south (Guangdong and Guangxi), the
north (Beijing and Jilin) and the central part (Hebei and
Henan) of China. All the samples were obtained from
patients with chronic HBV infection. Among the 642
samples, 36 were from Jilin (The First Affiliated Hospital
of Jilin University), 163 were from Beijing (Beijing Ditan
Hospital), 61 were from Guangdong (Peking University
Shenzhen Hospital), 49 were from Guangxi (Guangxi
Provincial Center for Disease Control and Prevention),
24 were from Shandong (Shandong Jining Infectious
Disease Hospital), 124 were from Jiangsu (Jiangsu Pro-
vincial Center for Disease Control and Prevention), 118
were from Xinjiang (The First Affiliated Hospital of
Xinjiang Medical University), 32 were from Henan
(Zhengzhou Municipal Center for Disease Control and
Prevention) and 35 were from Hebei (Handan Municipal
Center for Disease Control and Prevention).
Informed consent was obtained from each patient at
the time that serum samples were collected for the pur-
pose of HBV testing. The serum samples were trans-
ported on dry ice and stored at −80 °C in our lab until
analyzed.
The study was approved by the Ethics Committee of
Peking University Health Science Center in accordance
with the Helsinki Declaration.
Primer design
For primer design, 150 entire nucleotide sequences of
HBV genotypes A-H were retrieved from GenBank, and
analyzed by DNAStar software. Primers were then
designed in the conserved regions of the HBV genome
by Primer Premier 5.0 software. Primer sequences within
the same genotype or subgenotype differed by ≤ 2
nucleotides (a strict match at the 3’ end was ensured),
while primer sequences differed by ≥3 nucleotides (usu-
ally ≥2 nucleotides at the 3’ end) among the different
genotypes or subgenotypes. Some primers were modified
by nucleotide substitutions in the middle or at the 5’ end
of primers to avoid intra- or inter-primer dimer
formation.
The first round PCR primers (outer primer pairs) were
designed in the regions of partial X-PreC/C genes (pri-
mers BF and HBAS-4 V) and partial P-PreS/S genes
(primers PF and S4R) for the amplification of all A-D
genotypes. In the second round amplification, three
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ing multiple primers. Mix A contained sense primers
HB (type B specific), DF (type D specific), C1F (subgeno-
type C1 specific), C2F (subgenotype C2 specific) and
antisense common primers BJA-RV and PR. These pri-
mers were used to identify genotypes B, D and subgeno-
types C1, C2. Mix B contained sense primers AF1, AF2
and antisense primer BA1R (AF1 and AF2 were degener-
ate primers, all three primers were type A specific).
These primers were used to identify genotype A. Mix C
contained sense primer HB (type B specific) and anti-
sense primers BA (subgenotype B2 specific), BJ (subge-
notype B1 specific). These primers were used to identify
subgenotypes B1 and B2. Genotypes A-D and subgeno-
types B1, B2, C1 and C2 could be differentiated based
on the length of the PCR products. HBAS-4 V and BJA-
RV were designed by Sugauchi et al., (2003) [28]. Primer
BA1R was designed by Naito et al., (2001) [15]. All the
primers were synthesized by Shanghai Sangon Biological
Engineering Technology & Services, China. The
sequences and the positions of the primers were shown





BF 5’- ACG GGG CGC ACC TCT CTT TA -3’ 1 519–1 538
HBAS-4 V 5’- ATA GGG GCA TTT GGT GGT CT -3’ 2 316–2 297
PF 5’- TTA TGC CTG CTA GGT TYaT ATC C -3’ 2 635–2 656
S4R 5’- AGA AGA TGA GGC ATA GCA GC -3’ 434-415
Second PCR
Mix A
HB 5’- ACC GTG AAC GCC CAC MbGG AA -3’ 1 617–1 636
BJA-RV 5’- TTC TTT ATA CGG GTC AAT GTC CAT G -3’ 1 924–1 900
DF 5’- GCA GAA TCT TTC CAC CAG -3’ 2 853–2 870
C1F 5’- TCA CTC CRcC CAC ACG GCA A -3’ 3 047–3 065
C2F 5’- CAC CGA ACA TGG AGA RcCA CA -3’ 147-166
PR 5’- TTG GTG AGT GAT TGG AGG TTG -3’ 341-321
Mix B
AF1 5’- GCC TAC TAG ATT CTA TCC TAC CCA C -3’ 2 645–2 669
AF2 5’- GCC TAC TAG ATT TTA TCC TAA CAG C -3’ 2 645–2 669
BA1R 5’- CTC GCG GAG ATT GAC GAG ATG T -3’ 111-132
Mix C
HB 5’- ACC GTG AAC GCC CAC MbGG AA -3’ 1 617–1 636
BA 5’- GTG TCG AGRc AGA TCT CGA ATA -3’ 1 998–1 978
BJ 5’- TGA TCT TTA GGC CCA TGT TAG T -3’ 2 192–2 171
a Y: C or T.
b M: A or C.
c R: A or G.DNA extraction and amplification
Hepatitis B virus DNA was extracted from 200 μl serum
samples using a QIAamp DNA Blood Kit (Qiagen, Hil-
den, Germany).
In the first round amplification, the following compo-
nents were added to each microcentrifuge tube: 2 μl 10×
buffer containing 1.5 mM MgCl2, 0.4 μl dNTP (10 mM),
1 μl each of primer BF (10 μM) and HBAS-4 V (10 μM),
0.6 μl each primer PF (10 μM) and S4R (10 μM), 1.5
units of Taq DNA polymerase (Dongsheng Biotech,
Guangzhou, China) and 5 μl template, and then distilled
deionized H2O (ddH2O) was added to make a total re-
action volume of 20 μl. The thermocycler (iCycler™;
Bio-Rad, Hercules, CA, USA) was programmed to prede-
nature the samples at 95 °C for 5 min followed by 40
cycles: 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 1 min.
Final elongation was at 72 °C for 7 min. In the second
round of amplification, 3 reactions were performed using
the 3 mixes of primers. For the mix A reaction, the fol-
lowing components were added to each microcentrifuge
tube: 2 μl 10× buffer containing 1.5 mM MgCl2, 0.4 μl
dNTP (10 mM), 1 μl each primer (10 μM) of mix A, 1
unit of Taq DNA polymerase and 1 μl PCR products of
the first round amplification, then ddH2O was added to
make a total reaction volume of 20 μl. The amplification
program was the same as that of the first round PCR ex-
cept the elongation time was decreased to 45 s. Amplifi-
cations with mix B and mix C were exactly the same as
those with mix A, except for the primers of each mix.
The PCR products of the second amplification, together
with molecular weight standards (Takara Bio, Shiga,
Japan), were electrophoresed on 2% agarose gels stained
with ethidium bromide and examined under UV light
using the Bio-Rad Gel Doc 2 000 System (Bio-Rad La-
boratories, Segrate, Milan, Italy).
The standard precautions were taken to avoid contam-
ination during PCR, and a negative control was included
in each run of tests to ensure the specificity.
Evaluating the sensitivity of the nPCR method
The quantitation of HBV DNA was determined using
the Abbott RealTime HBV DNA assay System, as
described previously by Ciotti et al., (2008) [29]. HBV
DNA was extracted from 200 μl of serum during the
sample preparation procedure. The limit of detection
was 15 IU/mL (101.18 IU/mL).
The serially diluted plasmids and 127 serum samples,
of which the HBV DNA levels were quantitated using
the Abbott RealTime HBV DNA Assay System, were
used for evaluating the sensitivity of the nPCR method.
Evaluating the specificity of the nPCR method
First, the plasmids and the standard serum panels were
applied for evaluating the specificity of the nPCR
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then assayed by the nPCR method. Among them, 130
samples were selected randomly and their PCR products
were sequenced directly to confirm the genotypes and
subgenotypes detected by the nPCR method (Table 2).Evaluating the reproducibility of the nPCR method
The reproducibility of the nPCR method was evaluated
using 4 plasmids of genotypes A, B, C and D (105 IU/mL)
and 10 clinical samples (including 2 genotype B, 3 geno-
type C, 3 genotype D and 2 ungenotyped). For each plas-
mid and sample, the test was repeated ten times.DNA sequencing and phylogenic analysis
The primers used for sequencing were as follows: outer
primers of PreS/S region PF and S4R; inner primers of
PreS/S region SF (nt2817-2839) 5’ TCA CCA TAT ACA
TGG GAA CAA GA 3’, and PR3 (nt423-402) 5’ CAT
AGC AGC AGG ATG AAG AGG A 3’; outer primers of
RT region P5 (nt972-993) 5’-GTG GCT CCA GTT
CMG GAA CAG T-3’, and P2 (nt2194-2173) 5’-CTA
GGA GTT CCG CAG TAT GGA T-3’; inner primers of
RT region P3 (nt976-993) 5’-CTC CAG TTC CGG AAC
AGT-3’, and P4 (2170–2153) 5’-GCA GAG GAG CCA
CAA AGG-3’. Type-specific primers were adopted to
verify the genotypes/subgenotypes in mixed infection
samples. DNA sequencing was performed using Applied
Biosystems 3730 XL DNA Analyzer.
Phylogenic analysis was carried out using MEGA 4.0
software. The phylogenic trees were constructed by the
neighbor-joining method [30]. Bootstrap re-sampling
and reconstruction were carried out 1 000 times to con-

















Shandong 0 0 1 10 0 2 0 0 13
Guangdong 4 0 3 2 1 3 0 1 14
Guangxi 0 0 0 0 0 4 4 0 8
Henan 0 0 0 0 0 0 1 0 1
Hebei 0 0 0 3 0 0 0 0 3
Xinjiang 0 0 0 4 36 0 3 0 43
Jiangsu 21 1 0 24 0 2 0 0 48
Total 25 1 4 43 37 11 8 1 130Results
The sensitivity of the nPCR method
Serially diluted plasmids and clinical samples quantitated
using the Abbott RealTime HBV DNA Assay System
were used for evaluating the sensitivity of the method.
The genotypes of the plasmids could be identified
when the HBV DNA load was ≥101.18 IU/mL.
Of 8 clinical samples with viral loads <101.18 IU/mL, 3
(37.5%) could be genotyped successfully by the nPCR
method, while 15 of 38 (39.5%) clinical samples with
viral loads of 101.18 IU/mL-102.3 IU/mL could be geno-
typed successfully. However, 100% of the samples could
be genotyped when the viral load was ≥102.3 IU/mL
(Table 3).
The specificity of the nPCR method
The specificity of the primer pairs was evaluated using
the plasmids and standard serum panels as mentioned
above. As shown in Figures 1 and 2, the individual pri-
mer pairs and three multiplex mixes of primers (mix A,
mix B and mix C) exclusively amplified HBV of the re-
spective genotype/subgenotype, and no amplification of
other HBV genotypes/subgenotypes was observed.
Of the 642 samples tested, 639 (99.5%) were genotyped
and subgenotyped successfully. To confirm the results
detected by the nPCR method, 130 samples were
selected randomly from the 639 clinical samples as
shown in Table 2 (109 single-genotype infection samples,
one single-genotype infection sample coexistence of dif-
ferent subgenotypes and 20 samples coexistence of dif-
ferent genotypes), and their PCR products were
sequenced directly [GenBank: JQ416163-JQ416306,
HQ833465-HQ833471]. All the sequencing results were
consistent with those of the nPCR method.Table 3 Identification of HBV genotypes in clinical














A B C D Mix
<101.18 8 3 37.5 0 0 2 1 0
101.18 -102.3 38 15 39.5 0 0 12 3 0
102.3 - 103 25 25 100 0 1 21 0 1a + 2c
103 - 104 12 12 100 0 2 10 0 0
104 -105 4 4 100 0 1 3 0 0
105-106 6 6 100 0 1 5 0 0
106-107 4 4 100 0 1 3 0 0
107-108 12 12 100 0 3 8 0 1b
108 -109 18 18 100 0 4 13 0 1a
Total 127 99 78.0 0 13 77 4 5
a B and C mixed genotype infections.
b B1 and B2 mixed subgenotype infections.
c C and D mixed genotype infections.
(a) AF1/AF2/BA1R (b) HB/BJA-RV 
(c) HB/BA (d) HB/BJ
(e) C1F /PR (f) C2F/PR
(g) DF/PR 
Figure 1 The specificity of the individual primer pairs was evaluated using plasmids and standard sera containing the HBV genome.
Type-specific primers AF1/AF2/BA1R (Figure 1a) were used to amplify plasmids/standard sera of HBV genotype A (Lane 1), subgenotype B2 (Lane
2), subgenotype B1 (Lane 3), subgenotype C1 (Lane 4), subgenotype C2 (Lane 5) and genotype D (Lane 6). Lane 7 is the negative control, and
lane 8 is the molecular weight standard. The PCR product of genotype A was 709 bp. Type-specific primers of genotype B (Figure 1b), D (Figure
1g) and subgenotype B2 (Figure 1c), B1 (Figure 1d), C1 (Figure 1e) and C2 (Figure 1f) were also used to amplify from these samples. The PCR
products of genotype B, subgenotype B2, B1, C1, C2 and genotype D were 308 bp, 382 bp, 576 bp, 510 bp, 195 bp and 671 bp, respectively.
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For 4 plasmids of genotypes A, B, C and D (105 IU/mL)
and 10 clinical samples (including 2 genotype B, 3 geno-
type C, 3 genotype D and 2 ungenotyped), consistent
genotyping results were obtained from ten independent
experiments. The ungenotyped samples could not be
genotyped in these ten independent experiments.Geographical distribution of HBV genotypes and
subgenotypes
Among the 642 serum samples studied, the distribution
of HBV genotypes was as follows: genotype B: 72
(11.2%); genotype C: 438 (68.2%); genotype D: 46 (7.2%)
and 84 (13.1%) patients were mixed genotypes. There
was no other genotype found in this study. The
Figure 2 The specificity of the 3 multiplex mixes of primers (A,
B and C) evaluated using plasmids and standard sera
containing the HBV genome. M: molecular weight standards; Lane
6, 8 and 11: negative controls; Lane1 and 9: standard sera of
subgenotype B2; Lane 2 and 10: plasmid of subgenotype B1; Lane 3:
standard serum of subgenotype C1; Lane 4: plasmid of subgenotype
C2; Lane 5: plasmid of genotype D; Lane 7: plasmid of genotype A.
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with mixed HBV genotypes confirmed the results of
nPCR methods.Figure 3 Distribution of HBV genotypes among different areas of Chi
infection; N, the strains that were not genotyped by the nPCR method.Geographically, the predominant genotype in China
was genotype C (Figure 3 and Additional file 2),
accounting for 91.5% (182/199) in the north, 89.6% (60/
67) in the central area, 71.6% (106/148) in the east,
55.5% (61/110) in the south and 24.6% (29/118) in the
west of China. Genotype B was mainly found in the
south (21.8%, 24/110), the east (18.9%, 28/148) and the
west (11.9%, 29/118) of China, while it was only 2.0% in
the north and 3.0% in central China. Genotype D was
prevalent in the west (Xinjiang Uygur Autonomous Re-
gion). As for mixed genotype infection, B +C was pre-
dominant and could be detected in all part of China.
The major subgenotypes were B2 (87.5%, 63/72) among
genotype B, and C2 (92.9%, 407/438) of genotype C
(Table 4), and they were the predominant subgenotype in
all part of China as well. Subgenotype C1 was mainly
found in the south of China. Subgenotype B1 (0.6%, 4/642)
was found in Xinjiang. Mixed subgenotypes B1+B2 (0.6%,
4/642) and C1+C2 (0.9%, 6/642) were sporadicallyna detected by the nPCR method (n= 642). M, mixed genotype





B1 B2 B1+B2 BN C1 C2 C1+C2
East 96.4 (27/28) 3.6 (1/28) 0.9 (1/106) 99.1 (105/106)
West 28.6 (4/14) 42.9 (6/14) 21.4 (3/14) 7.1 (1/14) 93.1 (27/29) 6.9 (2/29)
South 100 (24/24) 39.3 (24/61) 54.1 (33/61) 6.6 (4/61)
North 100 (4/4) 100 (182/182)
Center 100 (2/2) 100 (60/60)
Total 5.6 (4/72) 87.5 (63/72) 5.6 (4/72) 1.4 (1/72) 5.7 (25/438) 92.9 (407/438) 1.4 (6/438)
N: the strain that could not be subgenotyped by nPCR.
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and had rarely been reported before.
Discussions
A relatively simple, rapid, economic and practical geno-
typing system with high sensitivity and specificity was
established based on the methods developed by Naito
et al., (2001) [15] and Sugauchi et al., (2003) [28]. Com-
pared with the classical type-specific PCR method estab-
lished by Naito et al., (2001) [15], low-cost common Taq
polymerase was used in our method. The cost of the
common Taq polymerase is roughly 40% of AmpliTaq
Gold DNA polymerase used in Naito’s method. When
common Taq polymerase was employed instead of
AmpliTaq Gold DNA polymerase in Naito’s method, the
specificity of the method was reduced (unpublished
data). Only a single nucleotide difference between type-
specific primers (e.g. antisense primer BB1R) and refer-
ence sequences of different genotypes may allow exten-
sion of mismatched primer-template. It was reported
that, in some instances, a single terminal 3'-mismatched
base did allow PCR amplification to proceed [31,32],
which reduced the specificity of type-specific PCR
method. In our method, primers specific for each HBV
genotype or subgenotype differed by ≥3 nucleotides (≥2
nucleotides at the 3’ end of the sequences). Double mis-
matches at 3’ end decreased the extension of mis-
matched primer-template. The sequencing results of 130
serum samples selected randomly from the 639 samples,
confirmed the specificity of our nPCR method.
The sensitivity of the nPCR method was evaluated
using serially diluted plasmids (101-109 IU/mL) and 127
clinical samples, in which HBV DNA was quantitated
using the Abbott RealTime HBV DNA Assay System.
The limit of detection was <101.18 IU/mL (Table 3) and
100% of the samples could be genotyped when the viral
load was ≥102.3 IU/mL, which was sufficient for routine
genotyping and subgenotyping. The sensitivity of Chen’s
method [12] using single-round PCR for detection of
genotype B and C was >104 IU/mL as we repeated thismethod in our lab. Therefore, we developed a nested
PCR method for HBV genotyping and subgenotyping to
improve the lower limit of single-round PCR method.
On the other hand, there were two fragments gener-
ated after the first round PCR reaction in the nPCR
method. One of the fragments, for the specific detection
of genotype B, was located mainly in the preC/C region
of the HBV genome, and another one, for detecting gen-
otypes C and D, was mainly in the preS/S region (see
Supplementary data 1). This design increased the sensi-
tivity and specificity of the detection of genotypes B, C
and D, while mixed strains could be detected more sen-
sitively as well. In this study, 13.1% (84/642) of the sam-
ples assayed by the nPCR method were mixed
genotypes. The sequencing analysis of HBV DNA from
the 21 cases with mixed HBV infection confirmed the
results of the nPCR method (random sampling cases
were 1/5 of total number of mixed infection samples).
Only three of the 642 samples could not be genotyped
or subgenotyped by the nPCR method. Two of the three
samples could not be genotyped and another one was
identified as genotype B but could not be subgenotyped
further by the nPCR method. The sequencing results of
the three samples revealed that the first 2 samples were
C/D recombinants. It was reported that this kind of C/D
hybrid emerged in the preS/S region between genotype
D and subgenotype C2, and belonged to genotype C.
The recombination fragment of genotype D was located
at the nt 10–799 or nt 10–1 499 region [33]. As primers
DF and C2F were designed at nt2 853–2 870 and nt147-
166 respectively, the nPCR method could not detect this
kind of C/D recombinant. Until now, whole genome se-
quencing was the only effective method to detect C/D
recombinants. The third sample, which was identified as
subgenotype B2 by sequencing, had a mutation in the
region where primer BA was designed, and the mutation
was exactly at the nucleotide position matching the 3’
end of the primer, which led to failure of detection by
the nPCR method. However, the frequency of this kind
of mutation was relatively low.
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and D were circulating in China. The results revealed
marked geographical differences in the distribution of
HBV genotypes. In the north and central China, geno-
type C was the predominant while the percentage of
other genotypes was low. In the south and the east of
China, the dominant genotypes were C and B. In the
west, the dominant genotype was D. It was obvious that
the percentage of mixed genotype infection was high in
the south and the west of China. As previously reported,
HBV infection rate with multiple genotypes was found
to be 31% in Shenzhen [34] (in the south of China), and
22%- 43.8% in Xinjiang [35,36] (in the west of China). In
China, studies on the subgenotype of HBV were seldom
reported. The predominant subgenotype was B2 and C2
in all parts of China.
Conclusions
In conclusion, an accurate, sensitive and cost-effective
nPCR genotyping method for the simultaneous detection
of the HBV genotypes A to D and subgenotypes B and C
has been established. The geographical distribution of
HBV genotypes and subgenotypes in the mainland of
China was mapped at the same time. Further investiga-
tion of HBV genotypes and subgenotypes using this
method will enrich the epidemiological data for HBV in
regions where genotypes A-D are predominant. This
method will provide a useful tool for clinical and epi-
demiological applications.
Additional files
Additional file 1 Figure S1: The positions of the type-specific primers
for the improved nPCR method.
Additional file 2 Table S1: The genotype distribution in nine provinces
located in different areas of China.
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